Cytek Biosciences (CTKB) Competitors

10x Genomics (NASDAQ:TXG) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership, community ranking and profitability.

Which has more risk & volatility, TXG or CTKB?

10x Genomics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Does the media prefer TXG or CTKB?

In the previous week, 10x Genomics had 15 more articles in the media than Cytek Biosciences. MarketBeat recorded 19 mentions for 10x Genomics and 4 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.17 beat 10x Genomics' score of 0.69 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation and earnings, TXG or CTKB?

Cytek Biosciences has lower revenue, but higher earnings than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$610.79M	1.63	-$182.63M	-$1.52	-5.37
Cytek Biosciences	$200.45M	2.38	-$12.15M	-$0.05	-74.40

Is TXG or CTKB more profitable?

Cytek Biosciences has a net margin of -5.05% compared to 10x Genomics' net margin of -29.90%. Cytek Biosciences' return on equity of -2.58% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-29.90%	-25.40%	-19.69%
Cytek Biosciences	-5.05%	-2.58%	-2.05%

Do insiders and institutionals hold more shares of TXG or CTKB?

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 10.0% of 10x Genomics shares are held by insiders. Comparatively, 9.6% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Do analysts recommend TXG or CTKB?

10x Genomics currently has a consensus target price of $19.79, indicating a potential upside of 142.47%. Cytek Biosciences has a consensus target price of $6.42, indicating a potential upside of 72.49%. Given 10x Genomics' stronger consensus rating and higher probable upside, equities research analysts clearly believe 10x Genomics is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.35
Cytek Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the MarketBeat Community favor TXG or CTKB?

10x Genomics received 40 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 51.24% of users gave 10x Genomics an outperform vote while only 45.83% of users gave Cytek Biosciences an outperform vote.

Company	Underperform	Outperform
10x Genomics	Outperform Votes 62 51.24%	Underperform Votes 59 48.76%
Cytek Biosciences	Outperform Votes 22 45.83%	Underperform Votes 26 54.17%

Summary

10x Genomics beats Cytek Biosciences on 11 of the 18 factors compared between the two stocks.